Aplastic Anemia Treated with Eltrombopag during Pregnancy
Aplastic anemia is a rare blood disorder characterized by pancytopenia and hypocellular bone marrow. In patients with aplastic anemia, pancytopenia sometimes worsens during pregnancy, and relapse of aplastic anemia in pregnancy is common. Nevertheless, only supportive care with blood products is the...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Obstetrics and Gynecology |
| Online Access: | http://dx.doi.org/10.1155/2022/5889427 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550398429233152 |
|---|---|
| author | Yuri Suminaga Yoshitsugu Chigusa Tadakazu Kondo Haruko Okamoto Yosuke Kawamura Mana Taki Masaki Mandai Haruta Mogami |
| author_facet | Yuri Suminaga Yoshitsugu Chigusa Tadakazu Kondo Haruko Okamoto Yosuke Kawamura Mana Taki Masaki Mandai Haruta Mogami |
| author_sort | Yuri Suminaga |
| collection | DOAJ |
| description | Aplastic anemia is a rare blood disorder characterized by pancytopenia and hypocellular bone marrow. In patients with aplastic anemia, pancytopenia sometimes worsens during pregnancy, and relapse of aplastic anemia in pregnancy is common. Nevertheless, only supportive care with blood products is the mainstay of treatment of aplastic anemia in pregnancy. Thus, the obstetric management and treatment of aplastic anemia in pregnancy is extremely challenging. We herein report the first case of a pregnant woman complicated with aplastic anemia who was successfully treated with eltrombopag, a thrombopoietin receptor agonist. A 27-year-old primigravida woman who had a history of aplastic anemia refractory to immunosuppressive therapy and was treated with eltrombopag became pregnant. Eltrombopag treatment was continued after weighing the benefits and potential risks. Throughout pregnancy, the woman’s pancytopenia did not progress, and she delivered a 2336 g baby vaginally at 38 weeks of gestation. Her postpartum outcome was uneventful, and the neonate did not develop thrombocytosis. Since the efficacy and safety of eltrombopag in pregnancy has not yet been established, its routine use should be avoided. However, if limited to refractory cases and with adequate maternal and fetal monitoring, including neonatal blood examinations, the use of eltrombopag for patients with aplastic anemia during pregnancy may be acceptable and result in favorable maternal and fetal outcomes. |
| format | Article |
| id | doaj-art-11c2b47a02ff47a9b6a87a0079cb1cd9 |
| institution | Kabale University |
| issn | 2090-6692 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Obstetrics and Gynecology |
| spelling | doaj-art-11c2b47a02ff47a9b6a87a0079cb1cd92025-02-03T06:06:48ZengWileyCase Reports in Obstetrics and Gynecology2090-66922022-01-01202210.1155/2022/5889427Aplastic Anemia Treated with Eltrombopag during PregnancyYuri Suminaga0Yoshitsugu Chigusa1Tadakazu Kondo2Haruko Okamoto3Yosuke Kawamura4Mana Taki5Masaki Mandai6Haruta Mogami7Department of Gynecology and ObstetricsDepartment of Gynecology and ObstetricsDepartment of Hematology and OncologyDepartment of Gynecology and ObstetricsDepartment of Gynecology and ObstetricsDepartment of Gynecology and ObstetricsDepartment of Gynecology and ObstetricsDepartment of Gynecology and ObstetricsAplastic anemia is a rare blood disorder characterized by pancytopenia and hypocellular bone marrow. In patients with aplastic anemia, pancytopenia sometimes worsens during pregnancy, and relapse of aplastic anemia in pregnancy is common. Nevertheless, only supportive care with blood products is the mainstay of treatment of aplastic anemia in pregnancy. Thus, the obstetric management and treatment of aplastic anemia in pregnancy is extremely challenging. We herein report the first case of a pregnant woman complicated with aplastic anemia who was successfully treated with eltrombopag, a thrombopoietin receptor agonist. A 27-year-old primigravida woman who had a history of aplastic anemia refractory to immunosuppressive therapy and was treated with eltrombopag became pregnant. Eltrombopag treatment was continued after weighing the benefits and potential risks. Throughout pregnancy, the woman’s pancytopenia did not progress, and she delivered a 2336 g baby vaginally at 38 weeks of gestation. Her postpartum outcome was uneventful, and the neonate did not develop thrombocytosis. Since the efficacy and safety of eltrombopag in pregnancy has not yet been established, its routine use should be avoided. However, if limited to refractory cases and with adequate maternal and fetal monitoring, including neonatal blood examinations, the use of eltrombopag for patients with aplastic anemia during pregnancy may be acceptable and result in favorable maternal and fetal outcomes.http://dx.doi.org/10.1155/2022/5889427 |
| spellingShingle | Yuri Suminaga Yoshitsugu Chigusa Tadakazu Kondo Haruko Okamoto Yosuke Kawamura Mana Taki Masaki Mandai Haruta Mogami Aplastic Anemia Treated with Eltrombopag during Pregnancy Case Reports in Obstetrics and Gynecology |
| title | Aplastic Anemia Treated with Eltrombopag during Pregnancy |
| title_full | Aplastic Anemia Treated with Eltrombopag during Pregnancy |
| title_fullStr | Aplastic Anemia Treated with Eltrombopag during Pregnancy |
| title_full_unstemmed | Aplastic Anemia Treated with Eltrombopag during Pregnancy |
| title_short | Aplastic Anemia Treated with Eltrombopag during Pregnancy |
| title_sort | aplastic anemia treated with eltrombopag during pregnancy |
| url | http://dx.doi.org/10.1155/2022/5889427 |
| work_keys_str_mv | AT yurisuminaga aplasticanemiatreatedwitheltrombopagduringpregnancy AT yoshitsuguchigusa aplasticanemiatreatedwitheltrombopagduringpregnancy AT tadakazukondo aplasticanemiatreatedwitheltrombopagduringpregnancy AT harukookamoto aplasticanemiatreatedwitheltrombopagduringpregnancy AT yosukekawamura aplasticanemiatreatedwitheltrombopagduringpregnancy AT manataki aplasticanemiatreatedwitheltrombopagduringpregnancy AT masakimandai aplasticanemiatreatedwitheltrombopagduringpregnancy AT harutamogami aplasticanemiatreatedwitheltrombopagduringpregnancy |